Trial · NCT00510068
Results by group91
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 91
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology | Everolimus 10 mg/Day | 11.04 | 95% Confidence Interval 8.41 to 13.86 | Months | |
| Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology | Placebo | 4.60 | 95% Confidence Interval 3.06 to 5.39 | Months | |
| Percentage of Participants With Objective Response Rate ( CR {Complete Response} OR PR {Partial Response}) | Everolimus 10 mg/Day | 4.8 | 95% Confidence Interval 2.3 to 8.7 | Percentage of participants | |
| Percentage of Participants With Objective Response Rate ( CR {Complete Response} OR PR {Partial Response}) | Placebo | 2.0 | 95% Confidence Interval 0.5 to 5.0 | Percentage of participants | |
| Overall Survival | Everolimus 10 mg/Day | 44.02 | 95% Confidence Interval 35.61 to 51.75 | Months | |
| Overall Survival | Placebo | 37.68 | 95% Confidence Interval 29.14 to 45.77 | Months | |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Everolimus 10 mg/Day | Ki67 <=2% (n: 7, 17) | 12.52 | 95% Confidence Interval 3.42 to 14.75 | Months |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Placebo | Ki67 <=2% (n: 7, 17) | 3.68 | 95% Confidence Interval 2.86 to 5.52 | Months |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Everolimus 10 mg/Day | 2% <Ki67 <=5% (n: 24, 13) | 10.94 | 95% Confidence Interval 5.55 to 16.59 | Months |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Placebo | 2% <Ki67 <=5% (n: 24, 13) | 8.48 | 95% Confidence Interval 3.78 to 13.83 | Months |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Everolimus 10 mg/Day | Ki67 >5% (n: 20, 22) | 7.69 | 95% Confidence Interval 5.59 to NA | Months |
| Progression Free Survival According to Ki-67 Levels Categorized as: Less Than or Equal to 2%, > 2% to Less Than or Equal to 5% and > 5% | Placebo | Ki67 >5% (n: 20, 22) | 3.15 | 95% Confidence Interval 2.79 to 5.55 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Everolimus 10 mg/Day | CgA Levels at baseline: CgA <= 2x ULN (n:121, 97) | 11.17 | 95% Confidence Interval 8.54 to 16.49 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Placebo | CgA Levels at baseline: CgA <= 2x ULN (n:121, 97) | 4.90 | 95% Confidence Interval 2.99 to 5.55 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Everolimus 10 mg/Day | CgA levels at baseline: CgA > 2x ULN (n:84, 103) | 8.54 | 95% Confidence Interval 7.69 to 13.80 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Placebo | CgA levels at baseline: CgA > 2x ULN (n:84, 103) | 4.34 | 95% Confidence Interval 2.86 to 5.39 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Everolimus 10 mg/Day | Early CgA response: Response (n: 48, 22) | 8.54 | 95% Confidence Interval 7.56 to 14.00 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Placebo | Early CgA response: Response (n: 48, 22) | 5.70 | 95% Confidence Interval 3.19 to 8.54 | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Everolimus 10 mg/Day | Early CgA response: Non-Response (n:40, 82) | 11.14 | 95% Confidence Interval 6.90 to NA | Months |
| Progression Free Survival According to Chromogramin A Tumor Marker (CgA) Baseline Level and According to CgA Early Response | Placebo | Early CgA response: Non-Response (n:40, 82) | 3.19 | 95% Confidence Interval 2.83 to 5.36 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00510068/results